Herr R - Search Results

1

Cardiovascular and metabolic risk profile in German patients with moderate and severe psoriasis: a case control study.

Warnecke C, Manousaridis I, Herr R, Terris DD, Goebeler M, Goerdt S, Peitsch WK. Warnecke C, et al. Among authors: herr r. Eur J Dermatol. 2011 Sep-Oct;21(5):761-70. doi: 10.1684/ejd.2011.1467. Eur J Dermatol. 2011. PMID: 21737374

2

Treatment satisfaction of patients with psoriasis.

Schaarschmidt ML, Kromer C, Herr R, Schmieder A, Goerdt S, Peitsch WK. Schaarschmidt ML, et al. Among authors: herr r. Acta Derm Venereol. 2015 May;95(5):572-8. doi: 10.2340/00015555-2011. Acta Derm Venereol. 2015. PMID: 25394584 Free article.

3

Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment.

Kromer C, Schaarschmidt ML, Schmieder A, Herr R, Goerdt S, Peitsch WK. Kromer C, et al. Among authors: herr r. PLoS One. 2015 Jun 9;10(6):e0129120. doi: 10.1371/journal.pone.0129120. eCollection 2015. PLoS One. 2015. PMID: 26058083 Free PMC article.

4

Patient Preferences for Treatment of Basal Cell Carcinoma: Importance of Cure and Cosmetic Outcome.

Martin I, Schaarschmidt ML, Glocker A, Herr R, Schmieder A, Goerdt S, Peitsch WK. Martin I, et al. Among authors: herr r. Acta Derm Venereol. 2016 Mar;96(3):355-60. doi: 10.2340/00015555-2273. Acta Derm Venereol. 2016. PMID: 26537095 Free article.

5

Patient Preferences for Biologicals in Psoriasis: Top Priority of Safety for Cardiovascular Patients.

Schaarschmidt ML, Kromer C, Herr R, Schmieder A, Sonntag D, Goerdt S, Peitsch WK. Schaarschmidt ML, et al. Among authors: herr r. PLoS One. 2015 Dec 3;10(12):e0144335. doi: 10.1371/journal.pone.0144335. eCollection 2015. PLoS One. 2015. PMID: 26633680 Free PMC article.

6

"Drug-Survival"-Raten und Gründe für den Abbruch von Systemtherapien bei Psoriasis.

Arnold T, Schaarschmidt ML, Herr R, Fischer JE, Goerdt S, Peitsch WK. Arnold T, et al. Among authors: herr r. J Dtsch Dermatol Ges. 2016 Nov;14(11):1090-1101. doi: 10.1111/ddg.13152_g. J Dtsch Dermatol Ges. 2016. PMID: 27879071

7

Drug survival rates and reasons for drug discontinuation in psoriasis.

Arnold T, Schaarschmidt ML, Herr R, Fischer JE, Goerdt S, Peitsch WK. Arnold T, et al. Among authors: herr r. J Dtsch Dermatol Ges. 2016 Nov;14(11):1089-1099. doi: 10.1111/ddg.13152. J Dtsch Dermatol Ges. 2016. PMID: 27879076

8

Behandlungspräferenzen für Biologika bei Psoriasis: erfahrene Patienten legen Wert auf Nachhaltigkeit.

Kromer C, Peitsch WK, Herr R, Schmieder A, Sonntag D, Schaarschmidt ML. Kromer C, et al. Among authors: herr r. J Dtsch Dermatol Ges. 2017 Feb;15(2):189-201. doi: 10.1111/ddg.12919_g. J Dtsch Dermatol Ges. 2017. PMID: 28214324

9

Treatment preferences for biologicals in psoriasis: experienced patients appreciate sustainability.

Kromer C, Peitsch WK, Herr R, Schmieder A, Sonntag D, Schaarschmidt ML. Kromer C, et al. Among authors: herr r. J Dtsch Dermatol Ges. 2017 Feb;15(2):189-200. doi: 10.1111/ddg.12919. J Dtsch Dermatol Ges. 2017. PMID: 28214326 Clinical Trial.

10

Patients' and Physicians' Preferences for Systemic Psoriasis Treatments: A Nationwide Comparative Discrete Choice Experiment (PsoCompare).

Schaarschmidt ML, Herr R, Gutknecht M, Wroblewska K, Gerdes S, Sticherling M, Augustin M, Peitsch WK. Schaarschmidt ML, et al. Among authors: herr r. Acta Derm Venereol. 2018 Feb 7;98(2):200-205. doi: 10.2340/00015555-2834. Acta Derm Venereol. 2018. PMID: 29110022 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

260 results

Search Page

Filters